AJANTPHARM - Ajanta Pharma Ltd. Share Price

Pharmaceuticals & Biotechnology

₹2568.80-41.90(-1.60%)

Market Closed as of Nov 6, 2025, 15:30 IST

Select time range

Valuation
Market Cap	30.85 kCr
Price/Earnings (Trailing)	33.24
Price/Sales (Trailing)	6.3
EV/EBITDA	22.44
Price/Free Cashflow	36.58
MarketCap/EBT	25.75
Enterprise Value	30.85 kCr

Fundamentals
Revenue (TTM)	4.9 kCr
Rev. Growth (Yr)	13.5%
Earnings (TTM)	929.96 Cr
Earnings Growth (Yr)	3.9%

Profitability
Operating Margin	24%
EBT Margin	24%
Return on Equity	24.54%
Return on Assets	18.54%
Free Cashflow Yield	2.73%

Price to Sales Ratio

Latest reported: 6

Revenue (Last 12 mths)

Latest reported: 5 kCr

Net Income (Last 12 mths)

Latest reported: 93 Cr

Growth & Returns
Price Change 1W	2.3%
Price Change 1M	3%
Price Change 6M	-4.7%
Price Change 1Y	-19.4%
3Y Cumulative Return	23.1%
5Y Cumulative Return	18.7%
7Y Cumulative Return	19.2%
10Y Cumulative Return	9.2%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	-376.52 Cr
Cash Flow from Operations (TTM)	1.16 kCr
Cash Flow from Financing (TTM)	-733.41 Cr
Cash & Equivalents	175.12 Cr
Free Cash Flow (TTM)	839.31 Cr
Free Cash Flow/Share (TTM)	67.19

Balance Sheet
Total Assets	5.01 kCr
Total Liabilities	1.22 kCr
Shareholder Equity	3.79 kCr
Current Assets	2.83 kCr
Current Liabilities	996.1 Cr
Net PPE	1.62 kCr
Inventory	903.85 Cr
Goodwill	0.00

Capital Structure & Leverage
Debt Ratio	0.00
Debt/Equity	0.00
Interest Coverage	46.43
Interest/Cashflow Ops	46.81

Dividend & Shareholder Returns
Dividend/Share (TTM)	54
Dividend Yield	1.95%
Shares Dilution (1Y)	0.00%
Shares Dilution (3Y)	-2.5%

Pros

Technicals: Bullish SharesGuru indicator.

Size: Market Cap wise it is among the top 20% companies of india.

Balance Sheet: Strong Balance Sheet.

Past Returns: Outperforming stock! In past three years, the stock has provided 23.1% return compared to 13.5% by NIFTY 50.

Profitability: Very strong Profitability. One year profit margin are 19%.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Growth: Good revenue growth. With 33.9% growth over past three years, the company is going strong.

Cons

Insider Trading: Significant insider selling noticed recently.

Smart Money: Smart money is losing interest in the stock.

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Investor Care
Dividend Yield	1.95%
Dividend/Share (TTM)	54
Shares Dilution (1Y)	0.00%
Earnings/Share (TTM)	74.31

Financial Health
Current Ratio	2.84
Debt/Equity	0.00

Technical Indicators
RSI (14d)	58.09
RSI (5d)	75.45
RSI (21d)	57.4
MACD Signal	Buy
Stochastic Oscillator Signal	Hold
Grufity Signal	Buy
RSI Signal	Hold
RSI5 Signal	Sell
RSI21 Signal	Hold
SMA 5 Signal	Buy
SMA 10 Signal	Buy
SMA 20 Signal	Buy
SMA 50 Signal	Sell
SMA 100 Signal	Sell

Latest News and Updates from Ajanta Pharma

Updated May 5, 2025

The Bad News

Devdiscourse

Despite strong financial results, Ajanta Pharma's shares fell by 2.65% to Rs 2,691.90 by market close.

Devdiscourse

Market concerns seem to overshadow the positive earnings reported by Ajanta Pharma.

Devdiscourse

The decline in share price raises questions about investor confidence despite the robust performance.

The Good News

Devdiscourse

Ajanta Pharma reported an 11% increase in profit after tax for Q4 FY2024-2025, reaching Rs 225 crore.

Devdiscourse

The company's revenue from operations increased to Rs 1,170 crore, compared to Rs 1,054 crore in the same quarter last year.

Devdiscourse

For the full fiscal year, Ajanta Pharma's profit after tax grew to Rs 920 crore and revenue climbed to Rs 4,648 crore.

Updates from Ajanta Pharma

Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 • 08 Oct 2025

Pls find enclosed herewith Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018.

General • 08 Oct 2025

Please find enclosed herewith Sustainability Report for FY 2025, prepared in accordance with the Global Reporting Initiative (GRI) Standards.

Analyst / Investor Meet • 08 Oct 2025

Pls find enclosed Investor Call Intimation

Newspaper Publication • 08 Sept 2025

Pls find enclosed Newspaper Advertisement

Newspaper Publication • 08 Sept 2025

Pls find enclosed Newspaper Advertisement

General • 02 Sept 2025

Please find enclosed intimation w.r.t Participation in Investor Conference.

General • 20 Aug 2025

Pls find enclosed Intimation under Regulation 30 of SEBI LODR Regulations 2015.

This information is AI-generated and may contain inaccuracies. Please verify from multiple sources.

Summary of Latest Earnings Report from Ajanta Pharma

Summary of Ajanta Pharma's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.

Earnings Outlook

Last updated:

Q&A Session

Last updated:

Share Holdings

Understand Ajanta Pharma ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

Shareholder Name	Holding %
Yogesh M Agrawal, trustee Yogesh Agrawal Trust	0.1447%
Rajesh M Agrawal, trustee Rajesh Agrawal Trust	0.1447%
Ravi P Agrawal, trustee Ravi Agrawal Trust	0.13%
Aayush M Agrawal, trustee Aayush Agrawal Trust	0.113%
Gabs Investments Pvt Ltd	0.1008%
Uti-Flexi Cap Fund	0.0341%
Ganga Exports being represented by Yogesh Agrawal, Rajesh Agrawal & Ravi Agrawal	0.0268%
Tata Aia Life Insurance Co Ltd-Whole Life Mid Cap Equity Fund-Ulif 009 04/01/07 Wle 110	0.0185%
Canara Robeco Mutual Fund A/C Canara Robeco Large And Mid Cap Fund	0.0161%
Kotak Small Cap Fund	0.0143%
Ravi P Agrawal	0.0023%
Aayush M Agrawal	0.0002%
Mannalal B. Agrawal	0%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Is Ajanta Pharma Better than it's peers?

Detailed comparison of Ajanta Pharma against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical Industries	4.06 LCr	55.67 kCr	+3.30%	-8.60%	39.05	7.29	-	-
CIPLA	Cipla	1.21 LCr	29.39 kCr	-0.80%	+2.60%	22.28	4.13	-	-
DRREDDY	Dr. Reddy's Lab	99.95 kCr	34.79 kCr	-3.80%	-6.00%	21.33	2.87	-	-
LUPIN	Lupin	89.97 kCr	23.61 kCr	-0.60%	-9.90%	24.3	3.81	-	-
AUROPHARMA	Aurobindo Pharma	66.44 kCr	32.56 kCr	+5.30%	-18.10%	19.62	2.04	-	-

Sector Comparison: AJANTPHARM vs Pharmaceuticals & Biotechnology

Comprehensive comparison against sector averages

Comparative Metrics

AJANTPHARM metrics compared to Pharmaceuticals

Category	AJANTPHARM	Pharmaceuticals
PE	33.16	35.83
PS	6.28	5.05
Growth	10.6 %	7 %

Performance Comparison

AJANTPHARM vs Pharmaceuticals (2021 - 2025)

Key Insights

1. AJANTPHARM is NOT among the Top 10 largest companies in Pharmaceuticals.
2. The company holds a market share of 1.1% in Pharmaceuticals.
3. In last one year, the company has had an above average growth that other Pharmaceuticals companies.

Income Statement for Ajanta Pharma

Consolidated figures (in Rs. Crores) / View Standalone Data

AnnualQuarterly

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	10.4%	4,648	4,209	3,743	3,341	2,890	2,588
Other Income	10.7%	94	85	99	116	26	92
Total Income	10.5%	4,743	4,293	3,841	3,457	2,916	2,680
Cost of Materials	-9.8%	847	939	878	779	706	560
Purchases of stock-in-trade	50.9%	250	166	146	136	90	112
Employee Expense	21.1%	1,090	900	785	646	548	486
Finance costs	222.1%	21	7.21	5.84	10	8.27	12
Depreciation and Amortization	6.7%	144	135	131	125	116	96
Other expenses	14.8%	1,228	1,070	1,124	934	698	763
Total Expenses	11.8%	3,553	3,179	3,096	2,547	2,015	2,012
Profit Before exceptional items and Tax	6.7%	1,189	1,114	745	909	900	668
Exceptional items before tax	-	0	0	0	0	0	-3.92
Total profit before tax	6.7%	1,189	1,114	745	909	900	664
Current tax	-3.1%	312	322	197	192	261	186
Deferred tax	-76%	-43.53	-24.3	-39.97	5.13	-15.05	9.92
Total tax	-9.8%	269	298	157	197	246	196
Total profit (loss) for period	12.8%	920	816	588	713	654	468
Other comp. income net of taxes	547.4%	1.85	0.81	15	-7.97	-6.45	5.56
Total Comprehensive Income	12.9%	922	817	603	705	647	473
Earnings Per Share, Basic	13.7%	73.56	64.82	45.89	54.966667	50.06	35.733333
Earnings Per Share, Diluted	13.7%	73.53	64.77	45.89	54.966667	50.06	35.733333

Description	(%) Q/Q	Jun-2025	Mar-2025	Dec-2024	Sep-2024	Jun-2024	Mar-2024
Revenue From Operations	11.4%	1,303	1,170	1,146	1,187	1,145	1,054
Other Income	47.1%	26	18	30	19	26	36
Total Income	11.8%	1,329	1,189	1,177	1,206	1,171	1,090
Cost of Materials	8.4%	207	191	210	207	238	259
Purchases of stock-in-trade	-35.4%	52	80	79	46	45	40
Employee Expense	8.2%	303	280	265	261	284	234
Finance costs	-16%	5.26	6.07	7.91	6.02	0.73	1.53
Depreciation and Amortization	2.6%	41	40	36	34	34	34
Other expenses	20.4%	373	310	302	353	263	278
Total Expenses	8.6%	998	919	869	916	849	812
Profit Before exceptional items and Tax	23.1%	331	269	307	290	322	278
Total profit before tax	23.1%	331	269	307	290	322	278
Current tax	19.7%	74	62	95	76	79	73
Deferred tax	106.9%	2.29	-17.81	-20.34	-2.35	-3.03	2.21
Total tax	74.4%	76	44	75	74	76	75
Total profit (loss) for period	13.4%	255	225	233	216	246	203
Other comp. income net of taxes	-180.8%	0.16	2.04	1.44	5.71	-7.34	-6.39
Total Comprehensive Income	12.8%	256	227	234	222	238	196
Earnings Per Share, Basic	14.4%	20.44	18	18.6	17.27	19.54	16.1
Earnings Per Share, Diluted	14.3%	20.43	18	18.59	17.26	19.53	16.09

Standalone figures (in Rs. Crores) / View Consolidated Data

AnnualQuarterly

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	8.8%	4,322	3,971	3,411	3,141	2,719	2,196
Other Income	3.5%	120	116	133	140	104	184
Total Income	8.7%	4,442	4,088	3,544	3,280	2,822	2,381
Cost of Materials	-9.8%	847	939	878	773	704	556
Purchases of stock-in-trade	13.7%	184	162	149	116	101	99
Employee Expense	21.2%	1,011	834	720	586	498	438
Finance costs	-37.9%	4.6	6.8	5.23	9.12	6.9	9.1
Depreciation and Amortization	6.1%	140	132	127	121	111	91
Other expenses	16.6%	1,094	938	986	831	573	562
Total Expenses	9.1%	3,262	2,991	2,844	2,380	1,920	1,764
Profit Before exceptional items and Tax	7.6%	1,180	1,097	700	901	902	617
Exceptional items before tax	-	0	0	0	0	0	-3.92
Total profit before tax	7.6%	1,180	1,097	700	901	902	613
Current tax	-7.2%	258	278	144	171	217	168
Deferred tax	-62.4%	5.14	12	-2.93	9.51	9.77	3.45
Total tax	-9.3%	263	290	141	181	226	172
Total profit (loss) for period	13.6%	917	807	559	720	676	441
Other comp. income net of taxes	-94%	-5.83	-2.52	-2.27	0.36	-1.33	-2.55
Total Comprehensive Income	13.2%	911	805	556	720	674	439
Earnings Per Share, Basic	14.5%	73.28	64.11	43.61	55.52	51.726667	33.7
Earnings Per Share, Diluted	14.6%	73.25	64.06	43.61	55.52	51.726667	33.7

Description	(%) Q/Q	Jun-2025	Mar-2025	Dec-2024	Sep-2024	Jun-2024	Mar-2024
Revenue From Operations	19.2%	1,209	1,014	1,102	1,129	1,077	926
Other Income	135.3%	41	18	33	40	28	34
Total Income	21%	1,249	1,032	1,135	1,169	1,106	960
Cost of Materials	8.4%	207	191	210	207	238	259
Purchases of stock-in-trade	-12.5%	50	57	40	43	45	40
Employee Expense	8.9%	281	258	246	242	266	216
Finance costs	18.2%	0.73	0.67	2.48	0.73	0.72	1.42
Depreciation and Amortization	2.6%	40	39	35	33	33	33
Other expenses	22.3%	335	274	266	317	238	243
Total Expenses	14.4%	920	804	803	860	795	734
Profit Before exceptional items and Tax	44.5%	329	228	332	309	311	226
Total profit before tax	44.5%	329	228	332	309	311	226
Current tax	84.2%	71	39	76	71	71	60
Deferred tax	142.6%	3.29	-4.38	3.32	3.09	3.11	3.42
Total tax	114.7%	74	35	80	74	75	63
Total profit (loss) for period	32.3%	255	193	252	235	236	163
Other comp. income net of taxes	-74.9%	-3.25	-1.43	-0.41	-1.56	-2.43	-0.93
Total Comprehensive Income	31.4%	252	192	252	233	234	162
Earnings Per Share, Basic	34.2%	20.41	15.46	20.16	18.75	18.77	12.92
Earnings Per Share, Diluted	34.3%	20.4	15.45	20.15	18.74	18.75	12.91

Balance Sheet for Ajanta Pharma

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022
Cash and cash equivalents	176.2%	175	64	129	262	330	329
Current investments	-35.2%	439	677	330	213	510	281
Loans, current	-91.9%	2.54	20	34	23	17	8.03
Total current financial assets	0.5%	1,803	1,794	1,761	1,646	1,918	1,806
Inventories	6.9%	904	846	828	786	816	749
Total current assets	1.6%	2,830	2,786	2,722	2,563	2,825	2,648
Property, plant and equipment	19.5%	1,625	1,360	1,384	1,397	1,408	1,397
Capital work-in-progress	-49.7%	176	349	256	205	209	182
Investment property	-	0	0	0	0	0	8.16
Non-current investments	0%	25	25	19	25	25	25
Loans, non-current	-	0	0	0	0	0	0
Total non-current financial assets	0%	34	34	28	36	36	37
Total non-current assets	8.8%	2,172	1,996	1,907	1,870	1,845	1,799
Total assets	4.7%	5,015	4,790	4,638	4,433	4,679	4,448
Borrowings, non-current	-170.4%	0	2.42	0	0	1.25	1.49
Total non-current financial liabilities	-90.6%	36	374	25	24	27	23
Provisions, non-current	-9.2%	80	88	40	23	24	20
Total non-current liabilities	-60.4%	229	577	175	152	152	140
Borrowings, current	-	2.59	0	1.49	0.91	0.18	0.01
Total current financial liabilities	100%	841	421	773	681	1,069	624
Provisions, current	-	23	0	18	12	14	9.94
Current tax liabilities	-25.9%	41	55	45	82	33	36
Total current liabilities	85.6%	996	537	895	799	1,139	705
Total liabilities	10%	1,225	1,114	1,071	951	1,291	844
Equity share capital	0%	25	25	25	25	25	26
Total equity	3.1%	3,790	3,677	3,567	3,482	3,388	3,603
Total equity and liabilities	4.7%	5,015	4,790	4,638	4,433	4,679	4,448

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022
Cash and cash equivalents	84.6%	49	27	62	200	269	264
Current investments	-35.2%	439	677	330	213	510	281
Loans, current	-91.9%	2.54	20	15	22	17	7.81
Total current financial assets	-0.3%	1,719	1,725	1,635	1,559	1,777	1,691
Inventories	6.5%	739	694	678	626	684	608
Current tax assets	-	0	0	0	0	0.83	0
Total current assets	0.7%	2,567	2,550	2,433	2,306	2,544	2,386
Property, plant and equipment	19.9%	1,622	1,353	1,377	1,389	1,400	1,389
Capital work-in-progress	-49.7%	176	349	256	205	209	182
Investment property	-	0	0	0	0	0	8.16
Non-current investments	-2.3%	43	44	37	43	43	43
Loans, non-current	-	0	0	0	0	0	0
Total non-current financial assets	-2%	51	52	46	54	54	55
Total non-current assets	6.7%	1,978	1,853	1,776	1,743	1,753	1,730
Total assets	3.2%	4,554	4,412	4,217	4,049	4,305	4,116
Total non-current financial liabilities	14.3%	25	22	24	24	26	21
Provisions, non-current	19.7%	80	67	40	23	24	20
Total non-current liabilities	6.9%	218	204	174	152	150	138
Total current financial liabilities	6%	532	502	514	447	859	428
Provisions, current	10%	23	21	18	12	14	9.94
Current tax liabilities	-71.9%	17	58	37	57	11	19
Total current liabilities	4.9%	711	678	629	541	908	491
Total liabilities	5.3%	929	882	804	693	1,058	629
Equity share capital	0%	25	25	25	25	25	26
Total equity	2.7%	3,625	3,530	3,414	3,356	3,246	3,487
Total equity and liabilities	3.2%	4,554	4,412	4,217	4,049	4,305	4,116

Cash Flow for Ajanta Pharma

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	222.1%	21	7.21	5.84	10	-	-
Change in inventories	-467.7%	-74.51	-12.3	-22.37	-25.66	-	-
Depreciation	6.7%	144	135	131	125	-	-
Impairment loss / reversal	91.8%	0.63	-3.49	5.37	7.85	-	-
Unrealised forex losses/gains	-8.5%	-10.31	-9.42	-14.08	-21.19	-	-
Adjustments for interest income	56.8%	59	38	18	4.08	-	-
Share-based payments	-35.9%	3.88	5.49	0.22	0.3	-	-
Net Cashflows from Operations	34.9%	1,480	1,097	943	801	-	-
Income taxes paid (refund)	3.5%	323	312	151	239	-	-
Other inflows (outflows) of cash	-	0	0	0	0.01	-	-
Net Cashflows From Operating Activities	47.4%	1,157	785	792	562	-	-
Cash payment for investment in partnership firm or association of persons or LLP	-	6.25	0	0	25	-	-
Proceeds from sales of PPE	-98.8%	1.14	13	0.73	18	-	-
Purchase of property, plant and equipment	109.9%	318	152	174	149	-	-
Interest received	65.4%	44	27	0.52	0.9	-	-
Other inflows (outflows) of cash	30.6%	0.16	-0.21	4.35	27	-	-
Net Cashflows From Investing Activities	-689.9%	-376.52	65	-559.6	-74.1	-	-
Proceeds from issuing other equity instruments	-	0.01	0	0	0	-	-
Payments to acquire or redeem entity's shares	-9.3%	353	389	1.44	354	-	-
Proceeds from borrowings	110.6%	1.1	0.06	0	0.23	-	-
Repayments of borrowings	-	0	0	0.49	0	-	-
Payments of lease liabilities	-6.7%	15	16	14	17	-	-
Dividends paid	-45.7%	349	642	90	82	-	-
Interest paid	532.4%	17	3.53	2.33	7.35	-	-
Other inflows (outflows) of cash	-	0	0	0.33	0	-	-
Net Cashflows from Financing Activities	30.2%	-733.41	-1,051.06	-107.87	-460.04	-	-
Effect of exchange rate on cash eq.	-260.8%	-1.67	0.26	-0.84	0.95	-	-
Net change in cash and cash eq.	122.4%	46	-200.34	123	29	-	-

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	-37.9%	4.6	6.8	5.23	9.12	-	-
Change in inventories	-1355%	-61.5	5.98	-48.67	-0.89	-	-
Depreciation	6.1%	140	132	127	121	-	-
Impairment loss / reversal	-	0.63	0	-0.84	7.56	-	-
Unrealised forex losses/gains	-8.5%	-10.31	-9.42	-14.08	-21.19	-	-
Dividend income	-25%	22	29	35	22	-	-
Adjustments for interest income	56.8%	59	38	25	12	-	-
Share-based payments	-22.5%	4	4.87	0.22	0.3	-	-
Net Cashflows from Operations	35.3%	1,336	988	862	736	-	-
Income taxes paid (refund)	12%	282	252	126	193	-	-
Other inflows (outflows) of cash	-	0	0	0	0.02	-	-
Net Cashflows From Operating Activities	43.5%	1,054	735	736	542	-	-
Cash payment for investment in partnership firm or association of persons or LLP	-	6.25	0	0	25	-	-
Proceeds from sales of PPE	-101.4%	0.85	12	0.57	18	-	-
Purchase of property, plant and equipment	107.9%	317	153	176	147	-	-
Dividends received	-25%	22	29	35	22	-	-
Interest received	29.7%	49	38	25	12	-	-
Other inflows (outflows) of cash	-101.8%	-0.13	0.44	4.35	27	-	-
Net Cashflows From Investing Activities	-437.1%	-349.6	105	-501.31	-66.04	-	-
Proceeds from issuing shares	-	0.01	0	0	0	-	-
Payments to acquire or redeem entity's shares	-9.3%	353	389	1.44	354	-	-
Payments of lease liabilities	-8.3%	12	13	12	14	-	-
Dividends paid	-45.7%	349	642	90	82	-	-
Interest paid	-83.1%	1.41	3.42	1.76	6.52	-	-
Net Cashflows from Financing Activities	31.7%	-715.71	-1,047.7	-105.12	-457.32	-	-
Effect of exchange rate on cash eq.	-260.8%	-1.67	0.26	-0.84	0.95	-	-
Net change in cash and cash eq.	93.2%	-13.18	-207.07	129	20	-	-

What does Ajanta Pharma Ltd. do?

Pharmaceuticals•Healthcare•Mid Cap

Ajanta Pharma is a prominent pharmaceuticals company headquartered in Mumbai, India. Operating under the stock ticker AJANTPHARM, the company boasts a market capitalization of Rs. 34,665.6 Crores.

As a specialty pharmaceutical formulation company, Ajanta Pharma, along with its subsidiaries, focuses on the development, manufacturing, and marketing of specialty pharmaceutical finished dosages. The company serves a diverse range of therapeutic segments, including:

Cardiology
Antidiabetic
Ophthalmology
Dermatology
Pain Management
Respiratory Areas

Ajanta Pharma offers a wide array of pharmaceutical products, which include tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company operates not only in India but also extends its services across Africa, the rest of Asia, the United States, and various international markets.

Founded in 1973, Ajanta Pharma has demonstrated notable financial success, with a trailing 12 months revenue of Rs. 4,643.7 Crores. The company is also committed to returning value to its investors, offering a dividend yield of 1.95% per year. In the last 12 months, shareholders received a dividend of Rs. 54 per share. Furthermore, Ajanta Pharma has engaged in buybacks, having repurchased 0.8% of its own stock last year, contributing to the stability of its share price.

With a reported profit of Rs. 897.9 Crores over the past four quarters and a 40% revenue growth over the last three years, Ajanta Pharma continues to establish itself as a profitable and thriving player in the pharmaceutical industry.

Industry Group:Pharmaceuticals & Biotechnology

Employees:8,073

Website:www.ajantapharma.com

AJANTPHARM - Ajanta Pharma Ltd. Share Price

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

Investor Care

Financial Health

Technical Indicators

The Bad News

The Good News

Updates from Ajanta Pharma

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Ajanta Pharma Ltd. do?